Serum lipoprotein(a) level as long-term predictor of cardiovascular mortality in a large sample of subjects in primary cardiovascular prevention: data from the Brisighella Heart Study-Reference-Cited by-同舟云学术

Serum lipoprotein(a) level as long-term predictor of cardiovascular mortality in a large sample of subjects in primary cardiovascular prevention: data from the Brisighella Heart Study

Published:2017-01 Issue: Volume:37 Page:49-55
ISSN:0953-6205
Container-title:European Journal of Internal Medicine
language:en
Short-container-title:European Journal of Internal Medicine

Author:

Fogacci Federica,Cicero Arrigo Francesco Giuseppe,D'Addato Sergio,D'Agostini Laura,Rosticci Martina,Giovannini Marina,Bertagnin Enrico,Borghi Claudio

Publisher

Elsevier BV

Subject

Internal Medicine

Reference43 articles.

1. cDNA sequence of human apolipoprotein(a) is homologous to plasminogen;McLean;Nature,1987

2. Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations;Boerwinkle;J Clin Invest,1992

3. Extreme lipoprotein(a) levels and risk of myocardial infarction in the general population: the Copenhagen City Heart Study;Kamstrup;Circulation,2008

4. Apolipoprotein(a) isoforms and the risk of vascular disease: systematic review of 40 studies involving 58,000 participants;Erqou;J Am Coll Cardiol,2010

5. Lipoprotein(a) as a cardiovascular risk factor: current status;Nordestgaard;Eur Heart J,2010

Cited by 44 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Association between lipoprotein(a), fibrinogen and their combination with all-cause, cardiovascular disease and cancer-related mortality: findings from the NHANES;BMC Public Health;2024-07-18

2. Lipoprotein (a) concentration as a risk factor for ischaemic stroke and its subtypes;NEUROL NEUROCHIR POL;2024

3. Estimating the Prevalence and Characteristics of Patients Potentially Eligible for Lipoprotein(a)-Lowering Therapies in a Real-World Setting;Biomedicines;2023-12-12

4. Sex X Time Interactions in Lp(a) and LDL-C Response to Evolocumab;Biomedicines;2023-12-11

5. Lipoprotein(a), Interleukin-6 inhibitors, and atherosclerotic cardiovascular disease: Is there an association?;Atherosclerosis Plus;2023-12